Clinical Research Directory

Inclusion Criteria: 1. Patients newly diagnosed with histologically confirmed non-keratinizing NPC. 2. Patients with Tumours staged as T1-4N+/TxN0-3. 3. No sign of distant metastasis (M0). 4. Satisfactory performance status (i.e., Karnofsky Performance Status ≥ 70 or ECOG \< 2) 5. Age 21 years or older. 6. Adequate bone marrow function by peripheral blood counts as demonstrated by the following laboratory values: 1. ≥ 3 × 109/L leucocytes 2. ≥ 1.5 × 109/L neutrophils 3. ≥ 9 g/dL of haemoglobin, and 4. ≥ 100 × 109/L platelets. 7. Normal liver function demonstrated by the following laboratory values: 1. Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) concentrations of \< 1.5x upper limit of normal (ULN) 2. Alkaline phosphatase (ALP) concentration \< 2.5x ULN 3. Bilirubin \< ULN. 8. Renal function: Creatinine clearance at ≥60 mL/min 9. Able to provide informed consent 7\. Induction chemotherapy before radical chemoradiation to nasopharynx and neck is permissible if no disease progression after induction chemotherapy Exclusion Criteria: 1. Edentulous patients 2. Extensive crown/ implant work to the teeth 3. Patients having basaloid squamous cell carcinoma or WHO keratinizing squamous cell carcinoma. 4. Patients who suffered from previous malignancies, except adequately treated basal cell or squamous cell skin cancer, and in-situ cervical cancer. 5. Received RT previously (except for non-melanomatous skin cancers outside the intended RT treatment area) 6. Patients who received previous surgery (except diagnostic) or chemotherapy for the primary tumours or lymph nodes or history of glossectomy. 7. Patient who had a prior diagnosis of diseases effecting saliva secretion or causing salivary glands impairment (i.e., Sjogren's syndrome, iodine cancer treatment), had a reported history of abnormal sense of taste or eating disorders. 8. Current heavy smokers (smoke \> 1 pack/day) or previous heavy smokers (stopped smoking less than 2 years and had smoked \> 1 pack/day). 9. Patients suffering from any severe intercurrent disease, which may incur unacceptable risk or negatively affect trial compliance. For example, unstable cardiac disease necessitating treatment, chronic hepatitis renal disease, poorly controlled diabetes (fasting plasma glucose greater 1.5x upper limit of normal), and emotional disturbance. 10. Pregnant or lactating women. 11. Inability to attend the full course of RT or planned follow-up/survey responses.